Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04257123 · ClinicalTrials.gov registry record · NA
SATISFY (geleSis100 Effects on AppeTIte Sensations, Feeding Behavior and Dietary energY)
A NA study of Appetitive Behavior, sponsored by Purdue University.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT04257123: Completed NA study of Appetitive Behavior, sponsored by Purdue University.
NCT04257123 is a NA study of Appetitive Behavior that has completed, run by Purdue University. The registered enrollment target is 31 participants, below the 54-participant average among 11 other Appetitive Behavior trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04257123, a NA study of Appetitive Behavior, has completed, sponsored by Purdue University.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
A recent clinical trial demonstrated the efficacy of Gelesis100 use for weight loss (Obes 2019;27:205-216). The present trial is designed to explore the mechanisms by which it may work, i.e. by suppressing hunger, altering food intake and/or altering the efficiency of energy extraction from food.
Primary Outcome
Hunger, fullness, desire to eat and thirst will be measured on visual analogue scales with end anchors of "not at all" to "extremely." Ratings will be captured via Qualtrics software. Also, subjects will be asked to indicate when, during the meals, they feel full on the first and last days of the Controlled-Feeding periods.
Conditions Studied
Interventions
- OTHER Placebo
- DEVICE Gelesis100
Study Locations (1)
Indiana
- Purdue Univeristy - West Lafayette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-01-07 |
| Est. Completion | 2021-12-31 |
| Phase | NA |
What the finished NCT04257123 record still lists
NCT04257123 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 54-participant average among 11 other Appetitive Behavior trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Appetitive Behavior appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04257123 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT04257123 about?
NCT04257123 is a clinical study titled "SATISFY (geleSis100 Effects on AppeTIte Sensations, Feeding Behavior and Dietary energY)". A recent clinical trial demonstrated the efficacy of Gelesis100 use for weight loss (Obes 2019;27:205-216). The present trial is designed to explore the mechanisms by which it may work, i.e. by suppressing hunger, altering food intake and/or altering the efficiency of energy extraction from food.
What is the current status of trial NCT04257123?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2020-01-07. Estimated completion is 2021-12-31.
What conditions does trial NCT04257123 study?
This clinical trial studies the following conditions: Appetitive Behavior.
What interventions are being tested in trial NCT04257123?
The interventions under investigation include: Placebo (OTHER), Gelesis100 (DEVICE).
Who is sponsoring clinical trial NCT04257123?
This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04257123 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Appetitive Behavior
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04257123's enrollment target sits among peer trials
31 7th of 11 higher than 5 of 11 other Appetitive Behavior trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Appetitive Behavior trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Food for Thought: Executive Functioning Around Eating Among Children
RECRUITING · NA
-
Validation of a Novel Cerebellar-striatal Satiety Circuit in Humans
RECRUITING · NA
-
Exercise, Brain Activity, and Weight Maintenance
RECRUITING · NA
-
Whole Grains, Gastric Emptying and Glycemic Response
COMPLETED · NA
-
Barley Beta-glucan, Glycemic Control, and Appetite
COMPLETED · NA
-
Effects of Concord Grape Juice Alone on Glycemia, Appetite and Cognitive Function in Healthy Adults
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI